Roche to buy back sterling bonds as debt falls
Hoffmann-La Roche, the Swiss pharmaceuticals group, has launched another buyback of its bonds, part of a multi-year process of paying back debt after its $47bn acquisition of Genentech in 2009.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts